Terns Pharmaceuticals: How to Shake Up the Leukemia Market with the Drug TERN-701

Terns Pharmaceuticals is a biopharmaceutical company in the clinical development phase. After exiting its own obesity development, all hopes are pinned on the leukemia drug TERN-701. With an impressive molecular response rate of up to 75% in clinical trials, the drug positions itself as a potentially superior and safer alternative to current market leaders. Thanks to a massive capital increase at the end of 2025 of approximately $650 million, Terns has an exceptionally large liquidity cushion. These reserves ensure operational activities and...